Clinical Trial Update: Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of Nonacog Beta Pegol (N9-GP) in previously untreated patients with Haemophilia B; results posted following tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Refixia (Nonacog Beta Pegol (N9-GP))

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2023-12-29